Dr. Raj joined the UT Southwestern faculty in 2006 after completing his urology training at Duke University Medical Center and his urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center.
He specializes in all aspects of urologic oncology, including the treatment of prostate, bladder, kidney, testis and penile cancers. He is experienced in both open and laparoscopic techniques. He has particular expertise in nerve-sparing radical prostatectomy, complex partial nephrectomy and orthotopic urinary diversion following radical cystectomy for bladder cancer. Dr. Raj’s clinical interests include optimizing oncologic and surgical outcomes for patients with urologic cancers utilizing minimally invasive approaches and multimodality approaches.
He is involved in setting up several clinical trials at UT Southwestern including those examining the role of pre-operative endorectal coil magnetic resonance imaging of prostate cancers and novel neoadjuvant chemotherapeutic approaches for patients with muscle-invasive bladder cancers.
His basic science research laboratory is involved in the development of novel therapeutics against the androgen receptor in prostate cancer. At UT Southwestern, Dr. Raj pioneered and developed several active small molecule compounds, called peptidomimetics against targeting coregulators-nuclear receptors including AR and ER. (Ravindranathan et al, Nature Communications 2013). These compounds have been licensed by a pharmaceutical company, with a goal towards clinical trials by early 2015. Dr. Raj’s laboratory has developed additional compounds targeting the AR in prostate cancer.
Dr. Raj has received peer reviewed funding from the US Department of Defense and Prostate Cancer Foundation. He is a co-recipient of the first ever US Department of Defense Prostate Cancer Research Program Transformative Grant ($US6.8 million). He recently developed a novel ex vivo culture methodology with Dr. Wayne Tilley for evaluation of primary cancer tissues (reviewed recently in Centenera et al, Nature Rev Urology). For further details of his research, please visit the Raj Lab website at http://www.utsouthwestern.edu/labs/raj/
Dr. Raj has received numerous honors for his work throughout his career, including the first prize from the American Urological Association for his laboratory research on prostate cancer. Dr. Raj has authored several high-impact publications in prestigious journals such as the Journal of Clinical Oncology, Lancet Oncology, Cancer and Molecular and Cellular Biology. He serves as reviewer for several peer-reviewed journals in the field of urology and oncology.
- Medical School
- Jefferson Medical School (1997)
- Duke University Medical Center (2004), Urology
- Memorial Sloan Kettering Cancer Institute (2006), Urologic Oncology
- Androgen receptor signaling
- Development of primary models of prostate and bladder cancers
- Development of targeted therapeutics
- Urologic cancers
- Tailoring Peptidomimetics for Targeting Protein-protein Interactions.
- Akram ON, Degraff DJ, Sheehan JH, Tilley WD, Matusik RJ, Ahn JM, Raj GV Mol. Cancer Res. 2014 Mar
- Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
- Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R Proc. Natl. Acad. Sci. U.S.A. 2014 Mar 111 11 4251-6
- Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
- Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA Oncogene 2014 Jan
- Emerging drugs for prostate cancer.
- Chung PH, Gayed BA, Thoreson GR, Raj GV Expert Opin Emerg Drugs 2013 Dec 18 4 533-50
- Ex vivo culture of human prostate tissue and drug development.
- Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM Nat Rev Urol 2013 Jun
- Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.
- Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV Nat Commun 2013 May 4 1923
- Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.
- Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV Mol. Endocrinol. 2012 Apr 26 4 550-61
- Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
- Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E Cancer 2011 Jan 117 2 276-82
- Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard.
- Raj GV, Bochner BH Semin. Oncol. 2007 Apr 34 2 110-21
- Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
- Raj GV, Iasonos A, Herr H, Donat SM J. Clin. Oncol. 2006 Jul 24 19 3095-100
Honors & Awards
- FREEMASONS FOUNDATION CENTRE FOR MENS HEALTH
Visiting Lectureship, Adelaide Australia (2014)
- FASEB CONFERENCE MERIT AWARD
Awarded to the top-rated abstract in steroid signaling (2010)
- ASCO FOUNDATION MERIT AWARD
Awarded to the top-rated abstract in genitourinary oncology (2008)
- ASCO Foundation Merit Award
Awarded to the top-rated abstracts in prostate cancer, Prostate Cancer Symposium, San Francisco, CA (2006)
- Society of Memorial Sloan Kettering Research Award
Awarded for perineural therapeutics and cavernous nerve injury, Society of Memorial Sloan Kettering (2005)
- AUA/Praecis Gerald P. Murphy Scholar
Distinction in the study of prostate cancer, AUA Annual Meeting, Orlando FL (2002)
- AUA Circon Basic Science Research Award (1st Place)
Laboratory research/ AUA Annual Meeting, Anaheim, CA (2001)
- Sigma Xi Research Award (1st Place)
Most outstanding basic science research of the year, Philadelphia Chapter, Sigma Xi Research Society, Philadelphia, PA (1994)
- American Urologic Association
- Society of Urologic Oncology